270 related articles for article (PubMed ID: 35694193)
1. Novel strategies for the mitigation of cytokine release syndrome induced by T cell engaging therapies with a focus on the use of kinase inhibitors.
Leclercq G; Steinhoff N; Haegel H; De Marco D; Bacac M; Klein C
Oncoimmunology; 2022; 11(1):2083479. PubMed ID: 35694193
[TBL] [Abstract][Full Text] [Related]
2. JAK and mTOR inhibitors prevent cytokine release while retaining T cell bispecific antibody in vivo efficacy.
Leclercq G; Haegel H; Toso A; Zimmermann T; Green L; Steinhoff N; Sam J; Pulko V; Schneider A; Giusti AM; Challier J; Freimoser-Grundschober A; Larivière L; Odermatt A; Stern M; Umana P; Bacac M; Klein C
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35064010
[TBL] [Abstract][Full Text] [Related]
3. Src/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodies.
Leclercq G; Haegel H; Schneider A; Giusti AM; Marrer-Berger E; Boetsch C; Walz AC; Pulko V; Sam J; Challier J; Ferlini C; Odermatt A; Umaña P; Bacac M; Klein C
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34326166
[TBL] [Abstract][Full Text] [Related]
4. Rationale for combining tyrosine kinase inhibitors and T cell redirecting antibodies to mitigate cytokine release syndrome (CRS).
Leclercq-Cohen G; Bacac M; Klein C
Expert Opin Biol Ther; 2023 Mar; 23(3):223-225. PubMed ID: 36629122
[No Abstract] [Full Text] [Related]
5. Cytokine Release Syndrome Associated with T-Cell-Based Therapies for Hematological Malignancies: Pathophysiology, Clinical Presentation, and Treatment.
Cosenza M; Sacchi S; Pozzi S
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299273
[TBL] [Abstract][Full Text] [Related]
6. Dissecting the mechanism of cytokine release induced by T-cell engagers highlights the contribution of neutrophils.
Leclercq G; Servera LA; Danilin S; Challier J; Steinhoff N; Bossen C; Odermatt A; Nicolini V; Umaña P; Klein C; Bacac M; Giusti AM; Schneider A; Haegel H
Oncoimmunology; 2022; 11(1):2039432. PubMed ID: 35186442
[TBL] [Abstract][Full Text] [Related]
7. Itacitinib (INCB039110), a JAK1 Inhibitor, Reduces Cytokines Associated with Cytokine Release Syndrome Induced by CAR T-cell Therapy.
Huarte E; O'Connor RS; Peel MT; Nunez-Cruz S; Leferovich J; Juvekar A; Yang YO; Truong L; Huang T; Naim A; Milone MC; Smith PA
Clin Cancer Res; 2020 Dec; 26(23):6299-6309. PubMed ID: 32998963
[TBL] [Abstract][Full Text] [Related]
8. Immunological analysis of the murine anti-CD3-induced cytokine release syndrome model and therapeutic efficacy of anti-cytokine antibodies.
Nouveau L; Buatois V; Cons L; Chatel L; Pontini G; Pleche N; Ferlin WG
Eur J Immunol; 2021 Aug; 51(8):2074-2085. PubMed ID: 33945643
[TBL] [Abstract][Full Text] [Related]
9. Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment.
Yan Z; Zhang H; Cao J; Zhang C; Liu H; Huang H; Cheng H; Qiao J; Wang Y; Wang Y; Gao L; Shi M; Sang W; Zhu F; Li D; Sun H; Wu Q; Qi Y; Li H; Wang X; Li Z; Liu H; Zheng J; Qian W; Zhang X; Xu K
Front Immunol; 2021; 12():611366. PubMed ID: 33708205
[TBL] [Abstract][Full Text] [Related]
10. A distinct cytokine network distinguishes chimeric antigen receptor T cell (CAR-T)-associated hemophagocytic lymphohistiocytosis-like toxicity (carHLH) from severe cytokine release syndrome following CAR-T therapy.
Zu C; Wu S; Zhang M; Wei G; Xu H; Cui J; Chang AH; Huang H; Hu Y
Cytotherapy; 2023 Nov; 25(11):1167-1175. PubMed ID: 37480884
[TBL] [Abstract][Full Text] [Related]
11. Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome.
Kotch C; Barrett D; Teachey DT
Expert Rev Clin Immunol; 2019 Aug; 15(8):813-822. PubMed ID: 31219357
[No Abstract] [Full Text] [Related]
12. Emerging approaches for preventing cytokine release syndrome in CAR-T cell therapy.
Balagopal S; Sasaki K; Kaur P; Nikolaidi M; Ishihara J
J Mater Chem B; 2022 Sep; 10(37):7491-7511. PubMed ID: 35912720
[TBL] [Abstract][Full Text] [Related]
13. Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy.
Acharya UH; Dhawale T; Yun S; Jacobson CA; Chavez JC; Ramos JD; Appelbaum J; Maloney DG
Expert Rev Hematol; 2019 Mar; 12(3):195-205. PubMed ID: 30793644
[TBL] [Abstract][Full Text] [Related]
14. Cytokine release syndrome and cancer immunotherapies - historical challenges and promising futures.
Shah D; Soper B; Shopland L
Front Immunol; 2023; 14():1190379. PubMed ID: 37304291
[TBL] [Abstract][Full Text] [Related]
15. TriTECM: A tetrafunctional T-cell engaging antibody with built-in risk mitigation of cytokine release syndrome.
Carrara SC; Harwardt J; Grzeschik J; Hock B; Kolmar H
Front Immunol; 2022; 13():1051875. PubMed ID: 36439165
[TBL] [Abstract][Full Text] [Related]
16. Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy.
Gazeau N; Liang EC; Wu QV; Voutsinas JM; Barba P; Iacoboni G; Kwon M; Ortega JLR; López-Corral L; Hernani R; Ortiz-Maldonado V; Martínez-Cibrian N; Martinez AP; Maziarz RT; Williamson S; Nemecek ER; Shadman M; Cowan AJ; Green DJ; Kimble E; Hirayama AV; Maloney DG; Turtle CJ; Gauthier J
Transplant Cell Ther; 2023 Jul; 29(7):430-437. PubMed ID: 37031746
[TBL] [Abstract][Full Text] [Related]
17. Using JAK inhibitor to treat cytokine release syndrome developed after chimeric antigen receptor T cell therapy for patients with refractory acute lymphoblastic leukemia: A case report.
Zi FM; Ye LL; Zheng JF; Cheng J; Wang QM
Medicine (Baltimore); 2021 May; 100(19):e25786. PubMed ID: 34106613
[TBL] [Abstract][Full Text] [Related]
18. Managing cytokine release syndrome associated with novel T cell-engaging therapies.
Maude SL; Barrett D; Teachey DT; Grupp SA
Cancer J; 2014; 20(2):119-22. PubMed ID: 24667956
[TBL] [Abstract][Full Text] [Related]
19. Toci or not toci: innovations in the diagnosis, prevention, and early management of cytokine release syndrome.
Banerjee R; Fakhri B; Shah N
Leuk Lymphoma; 2021 Nov; 62(11):2600-2611. PubMed ID: 34151714
[TBL] [Abstract][Full Text] [Related]
20. Extracorporeal cytokine removal in severe CAR-T cell associated cytokine release syndrome.
Stahl K; Schmidt BMW; Hoeper MM; Skripuletz T; Möhn N; Beutel G; Eder M; Welte T; Ganser A; Falk CS; Koenecke C; David S
J Crit Care; 2020 Jun; 57():124-129. PubMed ID: 32113143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
